A LinkedIn post from ABM Respiratory Care highlights the company’s presence at the ATS 2026 conference, where it is showcasing its BiWaze platform of airway clearance systems. The post notes demonstrations of BiWaze Clear, which the company describes as combining lung expansion, high-frequency oscillation, and nebulization into a single therapy.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post also references demonstrations of BiWaze Cough, emphasizing features such as a live waveform viewer to support titration and synchrony capabilities designed to align therapy with the patient’s cough cycle. By engaging clinicians, researchers, and respiratory care leaders at Booth 1803, the company appears to be targeting greater clinical visibility and potential adoption of its airway clearance technologies.
For investors, the post suggests a focus on clinical education and product differentiation in respiratory and pulmonary care, particularly in airway clearance and cough-assist segments. If these demonstrations translate into stronger clinician interest and subsequent commercial uptake, ABM Respiratory Care could reinforce its positioning in specialized respiratory devices and support longer-term revenue growth prospects.